Salute e Benessere
HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to Exhibit Remarkable Growth at a CAGR of 9.2% by 2034 | DelveInsight
Discover which therapies are expected to grab the major HPV16+ HNSCC market share @
HPV16-positive head and neck squamous cell carcinoma (HPV16+ HNSCC) is a type of cancer that arises in the mucosal surfaces of the oropharynx due to persistent infection with HPV16. Unlike traditional HNSCC, which is strongly linked to tobacco and alcohol use, HPV16+ HNSCC is primarily caused by high-risk HPV infection, often transmitted through oral sexual contact.
Symptoms may include a persistent sore throat, difficulty swallowing, hoarseness, ear pain, enlarged lymph nodes, and unexplained weight loss. This cancer tends to present with small primary tumors but significant lymph node involvement. Diagnosis involves a combination of physical examination, imaging (CT, MRI, or PET scans), and tissue biopsy. HPV status is confirmed using polymerase chain reaction (PCR) or in situ hybridization (ISH) to detect viral DNA, and p16 immunohistochemistry (IHC) serves as a surrogate marker for HPV-driven malignancy. HPV16+ HNSCC has a better prognosis and response to treatment compared to HPV-negative HNSCC, making accurate diagnosis crucial for therapeutic decisions.
The HPV16+ HNSCC epidemiology section provides insights into the historical and current HPV16+ HNSCC patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The HPV16+ HNSCC market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
The typical treatment for locoregionally advanced HPV16+ HNSCC involves chemoradiation (CRT) or surgery followed by adjuvant therapy. Despite this, recurrence and metastasis rates remain high, especially in later stages. and are the main PD-1 inhibitors approved for treating recurrent or metastatic HNSCC.
In November 2016 , the US FDA approved OPDIVO for treating patients with recurrent or metastatic SCCHN who experienced disease progression after platinum-based therapy. In April 2017 , the European Commission granted approval for OPDIVO as a monotherapy for adult patients with SCCHN progressing on or after platinum-based treatment.
In 2021, the UK's NICE recommended OPDIVO for patients with recurrent or metastatic HNSCC who had progression during or after platinum-based chemotherapy. OPDIVO was also approved in Japan in March 2017 for the treatment of relapse or distant metastasis of HNC. In April 2016 , BMS announced that the US FDA had given OPDIVO for the potential indication of recurrent or metastatic SCCHN following platinum-based therapy.
In June 2019 , the US FDA approved KEYTRUDA for use as a first-line treatment for patients with metastatic or unresectable recurrent HNSCC, including those with HPV. In August 2016 , KEYTRUDA received accelerated approval from the US FDA for the treatment of patients with recurrent or metastatic HNSCC who showed disease progression following platinum-based chemotherapy, also including those with HPV.
In November 2019 , Merck announced that the European Commission had approved KEYTRUDA as a first-line treatment for metastatic or unresectable recurrent HNSCC in patients whose tumors express PD-L1 (CPS ≥1). In December 2019 , Merck also reported that the Japan Pharmaceuticals and Medical Devices Agency (PMDA) had approved KEYTRUDA, both in combination with chemotherapy and as a monotherapy, for the first-line treatment of patients with recurrent or metastatic head and neck cancer (HNC).
KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, though only around 20% of patients respond, and HPV status does not significantly affect the response. Currently, there are no treatments specifically approved for HPV16+ cancers.
To know more about HPV16+ HNSCC treatment guidelines, visit @
Discover more about HPV16+ HNSCC drugs in development @
The HPV16+ HNSCC market dynamics are expected to change in the coming years. The , particularly HPV16+ HNSCC, is fueling demand for targeted therapies and preventive vaccines. As about the link between HPV16 and HNSCC, there is a rising focus on early diagnosis and preventive measures, including vaccination programs. The and aimed specifically at HPV16+ cancers is another significant driver, offering improved efficacy over conventional chemotherapy and radiation.
Additionally, the , especially in younger populations, is prompting healthcare providers and researchers to invest in better screening methods and treatment options. in oncology further contribute to the market's growth, creating opportunities for new treatments to emerge in this rapidly evolving space.
Apart from this, the landscape is highly competitive, with key players like , and others driving innovative strategies to improve efficacy and broaden treatment options for HPV16+ HNSCC, offering new hope for patients with limited current alternatives.
Furthermore, potential therapies are being investigated for the treatment of HPV16+ HNSCC, and it is safe to predict that the treatment space will significantly impact the HPV16+ HNSCC market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the HPV16+ HNSCC market in the 7MM.
Currently, a are being studied; the most encouraging findings have been seen when used in combination with checkpoint inhibitors as a first-line treatment for recurrent or metastatic disease. Although there are some studies looking at these vaccines in treatment-refractory patients, the response rate in that population tends to be lower. Additionally, ongoing trials are investigating the use of therapeutic vaccines without immunotherapy.
However, several factors may impede the growth of the HPV16+ HNSCC market. One of the primary challenges is the , which can make it difficult to develop targeted therapies that work universally across patient populations. Additionally, while HPV16+ HNSCC is linked to a distinct patient subgroup, there is a , resulting in late-stage diagnoses that reduce the efficacy of available treatments. also present obstacles, as the approval process for new therapies often involves and .
Moreover, HPV16+ HNSCC treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the HPV16+ HNSCC market growth may be offset by , , , and a . In addition, the about the disease may also impact the HPV16+ HNSCC market growth.
Download the report to understand which factors are driving HPV16+ HNSCC market trends @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV16+ cancers companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNSCC companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent HNSCC companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hpv16-positive-head-and-neck-squamous-cell-carcinoma-market-is-predicted-to-exhibit-remarkable-growth-at-a-cagr-of-9-2-by-2034--delveinsight-302383038.html